Detail Article

Informations générales (source: ClinicalTrials.gov)

Numéro NCT

NCT05544565 Suspendu

Titre

3-day Intravenous Antibiotic Treatment Versus 3-day Intravenous Followed by 7-day Oral Antibiotic Treatment for Acute Pyelonephritis in Children 1 Month to 3 Years Old: a Non-inferiority Open Randomized Multicentric Clinical Trial

Type

Interventional

Pathologie

Pyélonéphrite

Phase

Phase 4

Promoteur

Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)

Date de début

mars 2023

Date de fin

janvier 2027

Dernière mise à jour

02 octobre 2025

Résumé

Antibiotic therapies currently recommended for the treatment of acute pyelonephritis (AP) in children, whether fully by the oral route or initially intravenous (IV, 3 days) followed by the oral route, have a duration of 7 to 14 days (10 days in France). In children with no prior urological malformation, the global clinical and microbiological cure rate after antibiotic treatment completion is around 95%. Recurrence occurs in less than 5% of cases in the 3 months following AP. Renal scarring, when documented, concerns 15% of children 6 months after treatment. Renal scarring can be associated with chronic renal disease. The investigators hypothesize that 3 days of IV treatment is equivalent to extending to 10 days with an oral to treat AP in children. The investigators also hypothesize that while achieving equivalent clinical and prevention of re-infections in the following 3 months, 3 days of IV treatment reduces the risk of acquisition of resistant strains of Enterobacteriaceae and increases the gut microbotia diversity compared to extending to 10 days with an oral therapy.

Détail

Voir le détail 1.0 Hypothesis for the study Antibiotic therapies currently recommended for the treatment of acute pyelonephritis (AP) in children, whether fully by the oral route or initially intravenous (IV, 3 days) followed by the oral route, have a duration of 7 to 14 days (10 days in France). In children with no prior urological malformation, the global clinical and microbiological cure rate after antibiotic treatment completion is around 95%. Recurrence occurs in less than 5% of cases in the 3 months following AP. Renal scarring, when documented, concerns 15% of children 6 months after treatment. Renal scarring can be associated with chronic renal disease. The investigators hypothesize that 3 days of IV treatment is equivalent to extending to 10 days with an oral therapy to prevent long-term renal scarring. The investigators also hypothesize that while achieving equivalent clinical and microbiological success, and prevention of re-infections in the following 3 months, 3 days of IV treatment reduces the risk of acquisition of resistant strains of Enterobacteriaceae and increases the gut microbotia diversity compared to extending to 10 days with an oral therapy. 2.0 Description of knowledge relating to the condition in question Acute pyelonephritis (AP) is the most common proven bacterial infection in pediatric clinical practice. It can lead to sepsis or renal abscess and induce long-term complications such as renal scarring. Renal scarring during childhood can lead to hypertension or chronic renal disease at adult age, although the link between AP and chronic renal disease has not been firmly established. AP is most frequently due to Enterobacteriaceae, mainly Escherichia coli. Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) now account for 5% of AP in France and represent a serious threat to public health, owing to limited therapeutic options. The overall clinical success rate in children treated for AP is around 95% and is not significantly different when ESBL-E are implicated. In children with no prior urological malformation, recurrence in the following 3 months occurs in less than 5% of cases. Antibiotic treatment decreases the risk of renal scarring, which remains important, around 15% (95% CI: 11-18) in the largest meta-analysis. Moreover, delay in treatment of AP is associated with permanent renal scarring. In children without prior urological malformation, acute complications are exceptional, even in the presence of bacteraemia. Short courses of intravenous (IV) antibiotics (2-4 days) followed by oral therapy have proved to be as efficient as longer courses (7-14 days) of IV treatment. For children aged ≥ 1 month, oral treatment alone for 10 to 14 days has proved non inferior to initial IV antibiotics (2-4 days) followed by oral therapy (total 10 to 14 days). French Paediatric guidelines recommend a short course (up to 4 days) of IV amikacin and/or ceftriaxone followed by oral therapy (total 10 days), with the possibility, for children aged > 3 months of a 10-day course of oral cefixime [12]. In children initially treated IV, the oral relay occurs once the urine culture and antibiogram are available. The American Association of Pediatrics that focused on children aged 2 to 24 months recommends either an oral or a sequential IV/oral treatment for a total of 7 to 14 days, while the British NICE guidelines recommend an exclusively oral route only for children aged ≥ 3 months In practice, most centers initiate an IV treatment in a large subset of patients (ongoing practice analysis on the management of AP in children in France, personal data, to be published in 2021). An initial IV treatment is particularly used in young children, with an age cut-off varying between 3 months and 3 years according to the center. It is also used to secure the absorption of the treatment if the child vomits, is unable to take oral antibiotics or is severely unwell. The excellent short-term and the good long-term clinical outcomes in children treated for AP questions the need for a 10-day course of antibiotics. In adults, shorter treatments, such as amikacin for 5 days, have been validated for the treatment of uncomplicated AP. Recently published studies (Zaoutis 2023, Montini 2024) have compared a 5-day oral treatment vs 10-day oral treatment for AP in children. However, the first study (Zaoutis 2023) mainly included (63%) children with a non-febrile urinary tract infection (ie not an AP). The second only included children aged > 3 month. A practice survey conducted prior to our protocol had shown that many departments were already reluctant to treat infants under 1 year old, and particularly those under 3 months old, by oral route, warranting clinical trials including children < 3 month old. Third-generation cephalosporins (3GC), such as ceftriaxone, rapidly reduce the richness and diversity of the gut microbiota and also select subpopulations of resistant bacteria, particularly by acquisition of extended spectrum beta-lactamases, a major public health issue. There is no data on the impact of antibiotic relays on the gut microbiota. Since each antibiotic has its own anti-bacterial spectrum, a sequence of treatments could have an additive or even synergistic deleterious effect on the gut microbiota. This may in particular be the case in children treated with IV ceftriaxone for 3 days followed by cotrimoxazole for 7 days, as recommended in France in first intention. 3.0 Summary of relevant pre-clinical experiments and clinical trials 1999 Hoberman et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children This was a non-inferiority study between oral cefixime for 14 days and intravenous ceftriaxone for 3 days followed by oral cefixime for 11 days. One of the outcomes was the occurrence of renal scarring. It included children aged 1 to 24 months. A total of 306 children were included. Renal scarring at 6 months was noted in 9.8% children treated orally versus 7.2% of children treated intravenously. The study conclude that oral treatment was safe. The main limit of the study was the lower rate of renal scar in both arms compared to other studies, probably linked to a female/male sex ratio of 9:1 (with a median age of 8 months), when the sex ratio is in favour of boys before 1-year-old. 2007, Montini et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial This was a multicentre, randomised controlled, open labelled, parallel group, non-inferiority trial comparing oral co-amoxiclav for 10 days to parenteral ceftriaxone for three days, followed by oral co-amoxiclav for 7 days. Primary outcome was the rate of renal scarring after 12 months. A total of 502 children aged 1 month to <7 years with clinical pyelonephritis were included. Intention to treat analysis showed no significant differences between oral (n=244) and parenteral (n=258) treatment, both in the primary outcome (scarring scintigraphy at 12 months 27/197 (13.7%) v 36/203 (17.7%), and secondary outcomes: time to defervescence, white cell count at day 3, and percentage with sterile urine at day 3 (99.5% n both arms). The results were similar in the subgroups of children older and younger than 2 years (data not shown in the paper). 2012, Boquet et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children PHRC AOM 04 105; NCT00136656 This was a non-inferiority study between oral cefixime for 10 days and IV ceftriaxone for 4 days followed by oral cefixime for 6 days on the occurrence of renal scarring. It included children aged 1 to 36 mont with a first proven urinary tract infection and procalcitonin concentration ≥ 0.5 ng/mL s. The primary endpoint was the proportion of renal scar measured by 99mTc-DMSA renal scintigraphy 6 to 8 months after treatment. The study included a total 171 children of the 698 expected. The incidence of renal scarring was 30.8% in the oral treatment group and 27.3% for children who received the sequential treatment. The trial could not demonstrate statistically the non-inferiority due to insufficient enrolment. 2023, Zaoutis et al. Short-Course Therapy for Urinary Tract Infections in Children: The SCOUT Randomized Clinical Trial PMID: 37358858 ; NCT01595529, This was a randomized clinical noninferiority trial at 2 children's hospitals. Participants included children aged 2 months to 10 years with UTI exhibiting clinical improvement after 5 days of antimicrobials. The study compared another 5 days of antimicrobials (standard-course therapy) or 5 days of placebo (short-course therapy). The primary outcome, treatment failure, was defined as symptomatic UTI at or before the first follow-up visit (day 11 to 14 A total of 664 children were randomized (639 female [96%]; median age, 4 years): 2 of 328 assigned to standard-course (0.6%) and 14 of 336 assigned to short-course (4.2%) had a treatment failure. There were no differences between groups in rates of UTI after the first follow-up visit, incidence of adverse events, or incidence of gastrointestinal colonization with resistant organisms. 2024, Montini et al. Short Oral Antibiotic Therapy for Pediatric febrile Urinary Tract Infections: A Randomized Trial. [25] PMID: 38146260 This was a multicenter, investigator-initiated, parallel-group, randomized, controlled trial. We randomly assigned children aged 3 months to 5 years with a noncomplicated fUTI to receive amoxicillin-clavulanate for 5 or 10 days. The primary end point was the recurrence of a urinary tract infection within 30 days after the completion of therapy. Secondary end points were the difference in prevalence of clinical recovery, adverse drug-related events, and resistance to amoxicillin-clavulanic acid and/or to other antibiotics when a recurrent infection occurred. The study included a total of,175 children and 142 underwent randomization. The recurrence rate of UTI within 30 days of the end of therapy was 2.8% (2/72) in the short group and 14.3% (10/70) in the standard group. The recurrence rate of fUTI within 30 days from the end of therapy was 1.4% (1/72) in the short group and 5.7% (4/70) in the standard group. Fermer le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
CENTRE HOSPITALIER DE ST-DENIS	GASCHIGNARD Jean	En recrutement IDF	01/11/2025 07:55:21	Contacter
CENTRE HOSPITALIER SUD FRANCILIEN	GASCHIGNARD Jean	En recrutement IDF	01/11/2025 07:55:21	Contacter
CH D ORSAY	GASCHIGNARD Jean	En recrutement IDF	01/11/2025 07:55:21	Contacter
CH DE VERSAILLES SITE ANDRE MIGNOT	GASCHIGNARD Jean	En recrutement IDF	01/11/2025 07:55:21	Contacter
CH DES DEUX VALLEES SITE LONGJUMEAU	GASCHIGNARD Jean	En recrutement IDF	01/11/2025 07:55:21	Contacter
CHI DE CRETEIL	GASCHIGNARD Jean	En recrutement IDF	01/11/2025 07:55:22	Contacter
GRAND HOPITAL DE L'EST FRANCILIEN	GASCHIGNARD Jean	En recrutement IDF	01/11/2025 07:55:21	Contacter
AP-HP Assistance publique - Hôpitaux de Paris		En recrutement IDF	01/11/2025 07:55:23	Contacter
	AP-HP - Hôpital Ambroise Paré
	AP-HP - Hôpital Antoine Béclère
	AP-HP - Hôpital Bicêtre
	AP-HP - Hôpital Jean Verdier
	AP-HP - Hôpital Louis Mourier
	AP-HP - Hôpital Robert Debré
Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
AP-HP - Hôpital Robert Debré				Contact (sur clinicalTrials)
CH DE VERSAILLES SITE ANDRE MIGNOT				Contact (sur clinicalTrials)
CH SUD FRANCILIEN				Contact (sur clinicalTrials)
GHEF MARNE LA VALLEE SITE JOSSIGNY				Contact (sur clinicalTrials)
USLD HOPITAL D ORGEMONT MEAUX				Contact (sur clinicalTrials)
Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Andre mignot hospital - 78150 - Le Chesnay - Yvelines - France			01/11/2025 07:55:20	Contact (sur clinicalTrials)
CHU Toulouse - Toulouse 2972315 - France				Contact (sur clinicalTrials)
Jeanne Flandre Hospital - 59000 - Lille 2998324 - Nord - France				Contact (sur clinicalTrials)
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Ambroise Paré hospital - 92100 - Boulogne 3031141 - Hauts de Seine - France				Contact (sur clinicalTrials)
Antoine Beclère Hospital - 92140 - Clamart 3024783 - Haut de Seine - France				Contact (sur clinicalTrials)
Children-Teenager hospital - 44000 - Nantes 2990969 - Loire atlantique - France				Contact (sur clinicalTrials)
Intercomunal Créteil Hospital - 94000 - Créteil 3022530 - Val de Marne - France				Contact (sur clinicalTrials)
Jean Verdier Hospital - 93140 - Bondy 3031815 - Seine St Denis - France				Contact (sur clinicalTrials)
Kremlin Bicêtre Hospital - 94270 - Le Kremlin-Bicêtre 3003737 - Val de Marne - France				Contact (sur clinicalTrials)
Paris-Saclay hospital - 91400 - Orsay 2989204 - Essonne - France				Contact (sur clinicalTrials)

Critères

Genre

Tous

Nombre d'inclusion

Critère d'inclusion

Inclusion Criteria:

- Age ≥ 1 month and < 3 years

- For children younger than 3 months, gestational age > 34 WA

- First episode of urinary tract infection

- AP defined by temperature ≥ 38°C on day of diagnosis AND positive urinalysis (white
cell counts ≥ 10^4/mL) with a positive urine culture with one Gram- negative
bacillus ≥ 104 UFC/mL. The child temperature will have to be measured with a
thermometer according to the French national recommendations [Health Insurance
website (AMELI ;see: - https://www.ameli.
fr/assure/sante/bons-gestes/soins/prendre-temperature); HAS (see:
https://www.has-sante.
fr/jcms/c_2674284/fr/prise-en-charge-de-la-fievre-chez-l-enfant)].

- Initial treatment by either ceftriaxone AND/OR amikacin

- Outpatient or hospitalised

Non-inclusion Criteria:

- Urine collected by bag

- Urine culture growing more than one dominant bacterium (cf section 6.2 of the
protocol)

- Catheter-associated acute pyelonephritis

- Known congenital anomalies of the kidney and genitourinary tract (other than
vesicoureteral reflux and pyelocaliceal dilatation < 10 mm)

- Previous surgery of the genitourinary tract (except circumcision in male children)

- Abnormal renal function for age and weight (defined by a serum creatinine >40µmol/L
before 1 year and >75µmol between 1 year et 3 years)

- Known immunocompromising condition (e.g., HIV, primary immunodeficiency, sickle cell
disease, use of chronic corticosteroids or other immunosuppressive agents)

- Antibiotic prophylaxis for any reason OR antibiotic treatment in the last 7 days
(except treatment administered for the AP)

- Known hypersensitivity to at least one of the active substances /excipients:
ceftriaxone (including other cephalosporins and other beta-lactams) and amikacin
(including other aminoglycosids).

- Known hypersensitivity to at least one of the active substances /excipients:
cotrimoxazole (=sulfamethoxazole/trimethoprim) (including other drugs containing
sulfonamides) and cefixime (including other cephalosporins)

- Known blood dyscrasias (megaloblastic haematopoiesis)

- Known severe hepatic insufficiency

- Known G6PD deficiency

- No written consent from holders of parental authority

- Non-affiliation to a social security system (as beneficiary or entitled person)

- Children whose follow-up is not carried out in the centre

- Participation in another interventional or minimal risk trial

Randomization criteria :

- Three days of taking antibiotics (IV or IM) (no interruption or discontinuation)

- Positive urine culture with Gram negative bacillus ≥ 10^4 UFC/mL

- Favorable clinical outcome at day of randomization (D2 or D3) defined by temperature
< 38°C at day of randomization and absence of fever measured > 38°C for at least 12
hours AND no abdominal pain AND no feeding problem AND investigator agreement

- No renal abscess AND congenital anomalies of the kidney and genitourinary tract
(other than vesicoureteral reflux and pyelocaliceal dilatation < 10 mm) on the renal
ultrasound performed between D0 and day of randomization

- No more than 1 type of dominant bacteria on the urine culture

- Sensitivity to the initial antibiotic treatment

- Sensitivity to cefixime OR cotrimoxazole

Critère de non inclusion

NCT05544565 - 3-day Intravenous Antibiotic Treatment Versus 3-day Intravenous Followed by 7-day Oral Antibiotic Treatment for Acute Pyelonephritis in Children 1 Month to 3 Years Old: a Non-inferiority Open Randomized Multicentric Clinical Trial

Informations générales
Etablissements
Critères
Accès à la fiche NCT

Retour en haut